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Summary
Background: Chronic	hepatitis	C	(CHC)	is	associated	with	systemic	insulin	resistance,	
yet	there	are	limited	data	on	the	tissue‐specific	contribution	in	vivo	to	this	adverse	
metabolic	phenotype,	and	the	effect	of	HCV	cure.
Methods: We	examined	tissue‐specific	insulin	sensitivity	in	a	cohort	study	involving	
13	patients	with	CHC	compared	 to	12	BMI‐matched	healthy	 control	 subjects.	All	
subjects	 underwent	 a	 two‐step	 clamp	 incorporating	 the	use	of	 stable	 isotopes	 to	
measure	carbohydrate	and	lipid	flux	(hepatic	and	global	insulin	sensitivity)	with	con‐
comitant	subcutaneous	adipose	tissue	microdialysis	and	biopsy	(subcutaneous	adi‐
pose	tissue	insulin	sensitivity).	Investigations	were	repeated	in	seven	patients	with	
CHC	following	antiviral	therapy	with	a	documented	sustained	virological	response.
Results: Adipose	tissue	was	more	insulin	resistant	in	patients	with	CHC	compared	to	
healthy	controls,	as	evidence	by	elevated	glycerol	production	rate	and	impaired	insu‐
lin‐mediated	suppression	of	both	circulating	nonesterified	fatty	acids	(NEFA)	and	adi‐
pose	 interstitial	 fluid	 glycerol	 release	 during	 the	 hyperinsulinaemic	 euglycaemic	
clamp.	 Hepatic	 and	muscle	 insulin	 sensitivity	 were	 similar	 between	 patients	 with	
CHC	and	controls.	Following	viral	eradication,	hepatic	insulin	sensitivity	improved	as	
demonstrated	by	 a	 reduction	 in	 endogenous	 glucose	production	 rate.	 In	 addition,	
circulating	NEFA	decreased	with	sustained	virological	response	(SVR)	and	insulin	was	
more	effective	at	suppressing	adipose	tissue	interstitial	glycerol	release	with	a	paral‐
lel	 increase	 in	 the	 expression	of	 insulin	 signalling	 cascade	genes	 in	 adipose	 tissue	
consistent	with	enhanced	adipose	tissue	insulin	sensitivity.
Conclusion: Chronic	hepatitis	C	patients	have	profound	subcutaneous	adipose	tissue	
insulin	resistance	in	comparison	with	BMI‐matched	controls.	For	the	first	time,	we	
have	demonstrated	that	viral	eradication	improves	global,	hepatic	and	adipose	tissue	
insulin	sensitivity.
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1  | INTRODUC TION
Hepatitis	C	virus	(HCV)	infection	is	a	global	health	problem	affecting	
170	million	people	that	 leads	to	progressive	 liver	disease	 including	
cirrhosis	 and	 hepatocellular	 carcinoma	 (HCC).	 Chronic	 hepatitis	 C	
(CHC)	is	also	associated	with	metabolic	syndrome.1,2	Type	2	diabe‐
tes	mellitus	 (T2DM)	 is	more	prevalent	 in	 patients	with	CHC‐asso‐
ciated	 cirrhosis	 compared	 to	other	 causes	of	 cirrhosis.3 Metabolic 
syndrome	in	CHC	is	associated	with	an	increased	risk	of	progressive	
liver	diseases4	and	population‐based	studies	 link	T2DM	to	fibrosis	
and	highlight	its	role	as	a	risk	factor	for	developing	HCC.5
Hepatitis	C	virus	replicates	within	hepatocytes	 in	the	 liver	and	
yet	the	sites	of	insulin	resistance	in	patients	with	CHC	remain	elu‐
sive,	 with	 some	 studies	 reporting	 the	 liver	 as	 the	 primary	 site6,7 
and	others	 suggest	 extra‐hepatic	 sites,	 namely	 adipose	 tissue	 and	
skeletal	 muscle.8	 Most	 of	 the	 current	 evidence	 studying	 insulin	
resistance	 in	CHC	 is	based	on	homoeostatic	model	 assessment	of	
insulin	resistance	(HOMA‐IR)	which	cannot	distinguish	sites	of	IR9. 
Hepatic	steatosis	and	insulin	resistance	can	limit	treatment	response	
to	 interferon‐based	 therapies.10‐12	 Directly	 acting	 antiviral	 agents	
(DAAs)	have	recently	become	the	standard	of	care	with	high	rates	
of	 cure	 >90%.13‐15	 Curing	HCV	 infection	with	DAA	or	 interferon‐
based	therapies	improves	the	metabolic	profile16‐18;	however,	none	
of	these	studies	investigated	the	tissue‐specific	effects	of	HCV	in‐
fection	on	IR.
Based	upon	the	premise	that	CHC	is	a	multisystem	disease	with	
a	 significant	metabolic	burden,	we	 investigated	 the	 tissue‐specific	
contributions	 to	 the	 adverse	 metabolic	 phenotype	 in	 CHC	 using	
state‐of‐the‐art	 metabolic	 phenotyping	 techniques.	 Secondly,	 we	
assessed	the	impact	of	curative	treatments	on	liver	function	and	the	
adverse	metabolic	features	associated	with	CHC.	Our	underpinning	
hypothesis	 is	 that	 adipose	 tissue	 insulin	 resistance	 is	 the	 cardinal	
feature	of	the	metabolic	abnormalities	associated	with	chronic	hep‐
atitis	C	and	this	improves	with	viral	eradication.
2  | PATIENTS AND METHODS
2.1 | Study subjects
2.1.1 | CHC patients
One	hundred	and	two	treatment‐naive	patients	with	CHC	were	di‐
agnosed	as	anti‐HCV	antibody	positive	and	had	detectable	levels	of	
HCV	RNA.	Of	these,	13	met	the	 inclusion	criteria.	The	majority	of	
the	 patients	 were	 excluded	 because	 their	 treatment	 was	 delayed	
due	to	the	development	of	directly	acting	antiviral	agents.	Eligibility	
for	 the	 study	 was	 determined	 at	 routine	 national	 health	 service	
appointment	by	 standard	blood	 tests,	 clinical	 history	 and	physical	
examination/observations	 to	 identify	 coexisting	 medical	 illnesses	
or	other	contraindications	 (Supporting	Information	S1	 in	Appendix	
S1).	Patients	received	either	interferon‐containing	or	interferon‐free	
regimen,	which	was	 decided	 by	 the	 clinician	 following	 1‐1	 discus‐
sion.	The	types	and	duration	of	treatment	are	 listed	 in	Supporting	
Information	S2	in	Appendix	S1.	Of	the	thirteen	patients,	11	received	
antiviral	 therapy	 and	 two	 patients	 did	 not	 (contraindications	 to	
starting	treatment).	Of	the	11	treated	patients,	one	patient	did	not	
achieve	sustained	virological	response	(SVR),	two	patients	withdrew	
consent	and	one	patient	was	lost	to	follow‐up,	leaving	seven	patients	
who	completed	both	parts	of	the	study.
2.1.2 | Healthy control subjects
Twelve	healthy	male	volunteers	were	 recruited	by	 local	advertise‐
ment	and	provided	written	informed	consent.19
2.2 | Study design and clinical protocol
All	subjects	were	invited	to	the	Welcome	Trust	Clinical	Research	Unit	
where	 they	 underwent	 a	 two‐step	hyperinsulinaemic	 euglycaemic	
clamp,	adipose	tissue	microdialysis	and	biopsy,	magnetic	resonance	
spectroscopy	 (MRS)	 of	 the	 liver	 and	 dual	 energy	 absorptiometry	
(DXA)	scans	to	measure	body	composition	and	adipose	distribution.	
The	 first	part	of	 the	study	compared	healthy	volunteers	and	CHC	
patients	prior	to	treatment.	Following	successful	antiviral	treatment,	
seven	cured	patients	were	reinvited	to	undergo	a	similar	metabolic	
study	(second	part	of	study).	There	was	a	washout	period	of	at	least	
3	months	after	the	end	of	treatment	before	the	metabolic	study	was	
performed	(Supporting	Information	S3	in	Appendix	S1).
2.2.1 | Hepatic de novo lipogenesis
The	evening	prior	to	the	clinical	study,	subjects	visited	the	research	
facility	and	were	given	a	standardized	evening	meal	after	which	they	
fasted	until	the	end	of	the	clamp	at	14:00	hours	the	next	day.	To	de‐
termine	the	rates	of	de	novo	lipogenesis	(DNL),	they	were	given	oral	
2H2O	(3	g/kg	deuterated	water	 in	2	divided	doses)	at	5	and	10	pm,	
followed	by	drinking	water	enriched	to	0.4%.
2.2.2 | Two‐step hyperinsulinaemic 
euglycaemic clamp
At	 08:00	hours	 the	 following	morning,	 fasting	 bloods	 were	 taken	
prior	 to	 starting	 the	 two‐step	 clamp	 procedure	 using	 established	
methodology.19	A	bolus	of	13C‐glucose	(CK	Gas	Ltd,	Hook,	UK)	was	
administered	 (2	mg/kg)	 over	 1	minute	 followed	 by	 constant	 rate	
infusion	 of	 13C‐glucose	 (20	µg/kg/min;	 basal	 phase).	 Two	 hours	
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after	 starting	 the	clamp,	a	 soluble	 insulin	 infusion	 (Actrapid;	Novo	
Nordisk,	Copenhagen,	Denmark)	was	commenced	 (20	mU/m2/min,	
low	 insulin	 to	 partially	 suppress	 hepatic	 glucose	 output),	 together	
with	an	 infusion	of	20%	glucose	enriched	with	13C‐glucose	 to	4%,	
beginning	at	2	mg/kg/min	through	the	same	line.	Arterialized	blood	
samples	were	taken	at	5‐minute	intervals,	and	the	glucose	infusion	
rate	 changed	 to	maintain	 fasting	 glycaemic	 levels.	 After	 a	 further	
2	hours,	 the	 insulin	 infusion	 rate	 was	 then	 increased	 to	 100	mU/
m2/kg	(high	insulin	to	maximally	drive	glucose	uptake)	for	the	final	
2	hours	of	the	clamp	with	sampling	as	described	above.	Steady‐state	
samples	were	taken	at	three	time	points	 in	the	final	30	minutes	of	
each	phase	(basal,	low	insulin	and	high	insulin).	Rates	of	glucose	pro‐
duction	 and	 glucose	 disposal	 were	 calculated	 using	modified	 ver‐
sions	of	the	Steel	equations.20,21
2.2.3 | 2H5‐glycerol infusion
Whole	 body	 lipolysis	was	 assessed,	 by	measuring	 glycerol	 rate	 of	
appearance	 (Gly	 Ra)	 using	 stable	 isotope	 dilution	 methodology.	
2H5‐glycerol	 (0.1	μmol/kg/min)	 (CK	Gas	 Ltd)	was	 infused	 through‐
out	the	duration	of	the	clamp.	The	decrease	in	Gly	Ra,	from	basal	to	
low	and	high‐insulin,	reflects	the	suppression	of	lipolysis	by	insulin.	
Regression	analysis	 incorporating	the	circulating	insulin	concentra‐
tions	at	the	various	stages	of	the	clamp	was	used	to	determine	the	
insulin	 concentration	 needed	 to	 half‐maximally	 suppress	 Gly	 Ra	
(EC50).
2.2.4 | Subcutaneous adipose tissue (SAT) 
microdialysis and biopsy
A	 single	 microdialysis	 catheter	 (M	 Dialysis	 63	 40/30;	 Prospect	
Diagnostics	ltd,	Dronfield,	UK)	was	inserted	under	local	anaesthetic	
(1	mL	of	1%	lignocaine)	 into	the	subcutaneous	adipose	tissue	5	cm	
to	lateral	to	the	umbilicus.	Microdialysis	samples	were	taken	at	30‐
minute	intervals	for	the	duration	of	the	two‐step	clamp	as	we	have	
described	previously.22	 Thirty	minutes	 after	 starting	 the	 low‐dose	
insulin	 infusion,	 a	 subcutaneous	 abdominal	 adipose	 tissue	 biopsy	
was	performed	(contra‐lateral	to	the	microdialysis	catheter)	using	an	
aseptic	technique	under	local	anaesthetic	(1‐2	mL	of	1%	lignocaine),	
in	order	to	obtain	approximately	250‐500	mg	of	adipose	tissue.	The	
sample	was	immediately	snap	frozen	in	liquid	nitrogen	and	stored	at	
−80°C	 for	 subsequent	 total	 RNA	 extraction,	 reverse	 transcription	
and	real‐time	PCR	analysis.MRS,	DXA	protocol	and	isotope	analysis	
are	listed	in	Supporting	Information	S4	in	Appendix	S1.
2.3 | Ethics
The	study	was	conducted	in	accordance	with	the	guidelines	of	the	
Declaration	of	Helsinki	and	the	principles	of	Good	Clinical	Practice.	
All	 original	 study	 protocols	 had	 been	 reviewed	 and	 approved	 by	
the	local	National	Research	Ethics	Service	(NRES)	Committee	West	
Midlands,	 Solihull	 (East	 Midlands	 REC	 Centre)	 ethics	 committees	
REC	reference	12/WM/0122&12/WM/028.
2.4 | Statistics
Continuous	clinical	and	laboratory	variables	are	reported	as	mean	and	
standard	error	(SE)	since	all	variables	showed	parametric	distribution	
on	D'Agostino	and	Pearson	Omnibus	Normality	 testing.	Categorical	
variables	 are	 reported	 as	 number	 and	 percentages.	Area	 under	 the	
curve	 (AUC)	 analysis	 was	 performed	 using	 the	 trapezoidal	 method	
for	 interstitial	 glycerol	 release	 during	 the	 clamp.	 For	 comparison	 of	
single	variables,	paired	Student's	 t	 tests	were	used	 (or	nonparamet‐
ric	 equivalents	 where	 data	 were	 not	 normally	 distributed).	 Where	
repeated	 samples	were	 taken	 repeated‐measures	 one‐way	 ANOVA	
was	used,	incorporating	Dunnett's	test	for	multiple	comparisons.	The	
significance	level	was	set	at	P	<	0.05,	and	all	analyses	were	performed	
using	the	GraphPad	Prism	5.0	software	package	(GraphPad	Company,	
San	Diego,	CA,	USA).
3  | RESULTS
3.1 | Participants’ characteristics and systemic 
insulin sensitivity
Patient	 demographics,	 anthropometry	 and	 baseline	 biochemistry	
are	presented	 in	Supporting	 Information	Table	S5	 in	Appendix	S1.	
In	the	CHC	group,	eight	patients	were	infected	with	genotype	(Gt)1	
and	five	with	Gt3	HCV.	Serum	cholesterol,	triglycerides	and	creati‐
nine	were	all	lower	in	CHC	patients	compared	to	control	subjects.
3.2 | Differences in peripheral, hepatic and 
adipose tissue insulin sensitivity in CHC patients and 
control subjects
3.2.1 | Systemic insulin sensitivity and 
glucose disposal
Fasting	 glucose	 levels	 were	 similar	 in	 CHC	 and	 control	 subjects	
(4.39	±	0.1	 vs	 4.7	±	0.1	mmol/L,	 P	=	0.08)	 and	 were	 successfully	
maintained	across	the	clamp	(Figure	1A).	In	contrast,	fasting	insulin	
and	homoeostatic	model	assessment	for	insulin	resistance	(HOMA‐
IR)	were	 significantly	 increased	 in	 the	CHC	group	 consistent	with	
systemic	insulin	resistance.
Despite	 insulin	 infusion	 rates	 being	 similar	 between	 the	 two	
groups,	 low‐	 and	 high‐dose	 insulin	 concentrations	 were	 higher	 in	
the	CHC	group	(Figure	1B).	Glucose	utilization	under	high‐dose	in‐
sulin	 (M/I	values)	was	 lower	 in	patients	with	CHC.	However,	body	
weight‐adjusted	glucose	disposal	rates	(Gd)	were	similar	at	low‐	and	
high‐dose	insulin	infusion	(Figure	1C).
3.2.2 | Glucose production
Basal	glucose	production	rates	(Ra	Glucose)	were	significantly	higher	
in	CHC	patients	(Figure	1D)	although	endogenous	glucose	produc‐
tion	 (EGP),	 reflecting	 hepatic	 insulin	 sensitivity	 and	measured	 fol‐
lowing	 low‐dose	 insulin	 infusion,	 was	 similar	 between	 CHC	 and	
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healthy	 control	 subjects	 (0.71	±	0.10	 vs	 0.66	±	0.68	mg/kg/min,	
P	=	0.72)	(Figure	1D).
3.2.3 | Lipid metabolism
Proton	density	fat	fraction	measured	by	MRS	that	quantifies	hepatic	
lipid	content	was	similar	between	CHC	patients	and	healthy	control	
subjects	(1.5	±	0.7	vs	0.8	±	0.3%,	P	=	0.33).	However,	if	one	excludes	
HCV	 Gt1	 infected	 patients,	 the	 remaining	 Gt3	 patients	 showed	
increased	 hepatic	 lipid	 content	 compared	 to	 the	 control	 subjects	
(5.2	±	2.4	vs	0.8	±	0.3%,	P	=	0.01)	(Figure	2A).
Fasting	 circulating	NEFA	 levels	were	 similar	 between	CHC	pa‐
tients	 and	 control	 subjects	 in	 the	 basal	 and	 insulinaemic	 states	
(Figure	 2B).	 Ra	 glycerol,	 reflecting	 global	 lipolytic	 rates,	 was	 sup‐
pressed	by	 insulin.	 It	was	higher	 in	CHC	compared	to	control	sub‐
jects	in	the	basal	fasting	state,	after	low‐dose	and	high‐dose	insulin	
infusion	consistent	with	an	impaired	ability	of	insulin	to	suppress	lip‐
olysis,	largely	reflecting	adipose	tissue	insulin	resistance	(Figure	2C).
Adipose	tissue	microdialysis	was	used	to	examine	the	dynamic	
function	 of	 subcutaneous	 abdominal	 adipose	 tissue	 (SAT).	 Insulin	
suppressed	adipose	tissue	 interstitial	 fluid	glycerol	concentrations;	
however,	the	magnitude	of	this	suppression	following	low‐dose	in‐
sulin	 infusion	was	 comparable	 between	CHC	patients	 and	 control	
subjects.	 However,	 endorsing	 our	 observations	 with	 systemic	 Ra	
Glycerol,	 high‐dose	 insulin	 failed	 to	 suppress	 abdominal	 SAT	glyc‐
erol	 release	 in	 CHC	 (54	±	29	 vs	 179	±	26	μmol/kg/min,	 P	=	0.013)	
(Figure	2D).
3.3 | The impact of HCV eradication on liver 
chemistry, body composition and systemic insulin 
sensitivity
Body	 composition	 and	metabolic	 parameters	 including	 BMI,	weight,	
total	 and	android/gynoid	 fat	mass	and	serum	 lipids	were	unchanged	
before	 or	 after	 antiviral	 therapy.	 Alanine	 aminotransferase	 and	 as‐
partate	 aminotransferase	 improved	 after	 viral	 cure	 whilst	 gamma	
glutamyltransferase,	bilirubin	and	albumin	did	not	change	(Supporting	
Information	S6	in	Appendix	S1).	Gd	following	both	low‐	and	high‐dose	
insulin	infusion	was	unchanged	after	viral	cure	(Figure	3A).
3.4 | Viral eradication in CHC patients improves 
hepatic and adipose tissue insulin resistance
Following	 viral	 eradication,	 EGP	 improved	 (0.99	±	0.17	 vs	
0.72	±	0.18	mg/kg/min;	P	=	0.05)	consistent	with	increased	hepatic	
insulin	sensitivity	(Figure	3B).	Hepatic	steatosis	did	not	change	fol‐
lowing	viral	cure	(4.217	±	2.643	vs	2.893	±	1.257,	P	=	0.67).
Viral	cure	did	not	significantly	alter	the	contribution	of	DNL	to	
the	 circulating	 triglyceride	 pool	 (5.6	±	4.3	 vs	 4.3	±	4.7%,	P	=	0.68).	
Fasting	 circulating	 NEFA	 levels	 were	 reduced	 following	 viral	 cure	
(112	±	42	vs	80	±	39	μmol/L,	P	<	0.001).	Although	NEFA	levels	were	
suppressed	by	 low‐	and	high‐dose	 insulin	 infusions,	 there	were	no	
significant	 differences	 when	 comparing	 NEFA	 levels	 before	 and	
after	viral	eradication	(Figure	4A).
Ra	glycerol	 in	the	basal	fasting	state	or	after	low‐	or	high‐dose	
insulin	fusion	was	not	affected	by	viral	cure	 (Figure	4B).	Following	
viral	cure,	SAT	 interstitial	glycerol	 release	decreased	 in	the	fasting	
state,	consistent	with	enhanced	SAT	insulin	sensitivity	(261	±	128	vs	
194	±	43	μmol/kg/min,	P	<	0.05)	(Figure	4C).	However,	there	was	no	
difference	in	abdominal	SAT	glycerol	release	after	low‐dose	insulin	
infusion	(148	±	57	vs	145	±	62	μmol/kg/min,	P	=	0.23).	Importantly,	
viral	cure	enhanced	the	ability	of	high‐dose	insulin	infusion	to	sup‐
press	 local	 SAT	 glycerol	 release	 (99	±	23	 vs	 71	±	25	μmol/kg/min,	
P	<	0.05),	independent	of	CHC	genotype	(Figure	4C).
3.5 | HCV cure increases transcript levels of 
lipogenic and insulin signalling genes in subcutaneous 
adipose tissue
mRNA	 levels	 of	 genes	 involved	 in	 the	metabolic	 pathways	 includ‐
ing	 insulin	 sensitivity	 and	 lipid	 metabolism	 were	 analysed	 in	 SAT	
using	 a	 Fluidigm	 BioMark	 HD	 System	 96.96	 Dynamic	 Array,	 San	
F I G U R E  1  Hepatitis	C	virus	infection	
increased	systemic	insulin	resistance	
(IR),	with	limited	effect	on	hepatic	and	
peripheral	IR.	Circulating	glucose	(A)	
and	insulin	(B)	levels	were	measured	
during	the	two‐step	clamp.	Muscle	
and	hepatic	IR	was	determined	by	
suppression	of	glucose	disposal,	Gd	(C)	
and	rate	of	appearance,	Ra	(D).	Black	
bar	=	healthy	controls,	White	bar	=	CHC.	
****P	<	0.0001,**P	<	0.01,*P < 0.05
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Francisco,	CA,	USA	34	of	 the	58	 genes	 showed	 significant	 differ‐
ences	in	expression	levels	before	and	after	viral	eradication;	13	were	
involved	 in	 lipid	metabolism	 (Figure	5A)	 and	7	 in	 insulin	 signalling	
(Figure	5B)	(Supporting	Information	S3	in	Appendix	S1).	Specifically,	
mRNA	 levels	of	diacylglycerol	O‐acyltransferase‐1	 (DGAT1),	 leptin	
(LEP)	 and	 sterol	 regulatory	 element	 binding	 transcription	 factor‐1	
(SREBF1),	 the	 major	 regulator	 of	 lipogenic	 gene	 expression,	 were	
increased	 (2.4‐,4.8‐	 and	 3.5‐fold,	 respectively).	 mRNA	 expression	
F I G U R E  2  Hepatitis	C	virus	infection	
increased	adipose	tissue	insulin	resistance	
Hepatic	lipid	content	(by	magnetic	
resonance	spectroscopy/MRS)	(A)	and	
mean	circulating	nonesterified	fatty	acid	
(NEFA)	concentrations	(B),	measured	in	
controls	and	chronic	hepatitis	C.	Whole	
body	lipolysis	measured	by	Ra(glycerol)	
(C).	Change	in	mean	levels	of	glycerol	
release	from	basal	was	determined	
to	quantify	the	rate	of	lipolysis	in	
subcutaneous	adipose	tissue	at	low‐	and	
high‐dose	insulin	infusion	(D).	*P	<	0.05,	
**P	<	0.01,	***P	<	0.001
F I G U R E  3  Viral	eradication	in	chronic	
hepatitis	C	patients	improves	hepatic	
and	adipose	tissue	insulin	resistance.	The	
degree	of	skeletal	and	hepatic	insulin	
sensitivity	was	determined	by	suppression	
of	Gd	(A)	and	Ra	glucose	(B)	following	viral	
eradication
F I G U R E  4  Sustained	virological	
response	improves	global	and	
subcutaneous	adipose	tissue	(SAT)	insulin	
sensitivity.	Circulating	nonesterified	fatty	
acid	(NEFA)	concentrations	(A)	and	Ra	
glycerol	(B)	were	measured	to	determine	
global	insulin	resistance	and	whole	body	
lipolysis.	Mean	levels	of	glycerol	release	
during	steady	state	were	determined	
to	quantify	the	rate	of	lipolysis	in	
SAT.*P	<	0.05,	***P	<	0.001
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levels	of	insulin	receptor	substrate	(IRS)‐1	and	‐2	and	p‐akt	murine	
thymoma	viral	oncogene	homologue	(AKT)‐1	and	‐2	increased	3.6‐,	
8.1‐,	2.3‐	and	3.1‐fold,	respectively,	consistent	with	our	observations	
of	enhanced	insulin	action	after	antiviral	therapy.	mRNA	expression	
of	hydroxysteroid	11‐β	(HSD11β1)	and	dual	specificity	phosphatase	
1	 (DUSP1)	 were	 also	 increased	 (5.9‐	 and	 2.3‐fold,	 respectively).	
Taken	 together,	 these	data	 suggest	 a	 shift	 towards	 safe	 lipid	 stor‐
age	with	less	mobilization	in	the	setting	of	enhanced	insulin	action	
postviral	cure.
4  | DISCUSSION
We	have	demonstrated	that	CHC	is	associated	with	an	adverse	met‐
abolic	 phenotype	 characterized	 by	 systemic,	 hepatic	 and	 adipose	
tissue	IR	This	is	the	first	longitudinal	study	that	has	measured	both	
carbohydrate	 and	 lipid	 flux	 in	 HCV‐infected	 patients	 before	 and	
after	viral	cure	and	demonstrates	that	the	improvement	in	IR	upon	
successful	viral	eradication	was	specific	to	hepatic	and	subcutane‐
ous	adipose	tissue	with	limited	alterations	in	body	composition.
The	 association	 between	 HCV	 infection	 and	 T2DM	 is	 in‐
dependent	 of	 the	 presence	 of	 cirrhosis.23	 In	 vitro	 studies	 have	
demonstrated	 that	 HCV	 hijacks	 the	 lipid‐producing	 machinery	 of	
hepatocytes	for	its	benefit,	resulting	in	hepatic	steatosis	and	insulin	
resistance.	However,	 liver	cirrhosis	 (regardless	of	aetiology)	 is	also	
associated	 with	 insulin	 resistance.24,25	 The	 mechanisms	 by	 which	
these	occur	are	out	with	the	scope	of	this	study.	In	order	to	examine	
tissue‐specific	 insulin	sensitivity	 in	CHC,	only	patients	without	cir‐
rhosis	were	included	to	avoid	the	confounding	effect	of	cirrhosis	on	
insulin	resistance.
Our	CHC	cohort	had	lower	serum	triglyceride	levels	compared	
to	 control,	 despite	 being	well	 nourished	 and	 of	 normal	 BMI.	 This	
finding	 is	 similar	 to	 the	 observations	 by	Dai	 et	 al.26	 The	 associa‐
tion	between	HCV	and	hypobetalipoproteinaemia,27,28	in	part,	may	
explain	 the	observation.	However,	we	did	not	observe	 increase	 in	
triglyceride	 level	 following	viral	 eradication.	There	was	 significant	
hyperinsulinaemia	in	the	CHC	group	compared	to	control	subjects	
in	this	study.	In	patients	with	CHC,	the	presence	of	steatosis	or	ad‐
vanced	 fibrosis	was	 reported	 to	 associate	with	 a	 reduction	 in	he‐
patic	 insulin	 clearance.29	 Reduction	 in	 insulin	 clearance	 plays	 an	
important	role	in	the	compensatory	response	to	insulin	resistance,	
and	this	was	associated	with	increased	hepatic	lipase	activity.30	As	
our	study	excluded	patients	with	advanced	fibrosis	and	significant	
steatosis,	it	is	possible	that	HCV	may	mediate	hepatic	insulin	clear‐
ance	directly,	and	further	studies	are	needed	to	delineate	the	under‐
lying	mechanisms.
Our	 detailed	 metabolic	 phenotyping	 approach	 has	 allowed	 us	
to	dissect,	in	a	tissue‐specific	manner,	the	contribution	of	individual	
tissues	to	the	systemic	insulin	resistance	reported	in	HCV‐infected	
patients.	 Even	 though	 liver	 is	 the	major	 reservoir	 supporting	 viral	
replication,	the	sites	of	insulin	resistance	in	CHC	have	been	debated	
in	the	published	literature.6,8	Some	studies	have	suggested	that	the	
liver	is	the	major	site	of	insulin	resistance6,7	whilst	others	have	impli‐
cated	adipose	tissue	and	skeletal	muscle.8	The	mechanisms	under‐
lying	the	crosstalk	between	liver	and	extra‐hepatic	sites	also	remain	
largely	 unknown.	 The	 majority	 of	 studies	 published	 to‐date	 have	
used	HOMA‐IR	to	quantify	insulin	resistance	in	CHC31,32 which only 
provides	a	global,	systemic	measure	of	 insulin	sensitivity	and	does	
not	discriminate	between	hepatic	and	peripheral	effects.33
Despite	inducing	more	steatosis	and	fibrosis,	it	is	unclear	whether	
the	degree	of	insulin	resistance	is	linked	to	the	infecting	HCV	geno‐
types.	The	published	evidence	is	controversial,	with	some	suggest‐
ing	higher	insulin	resistance	among	patients	with	Gt134	whilst	others	
show	a	higher	prevalence	in	Gt3	infection.35	Some	authors	have	re‐
ported	data	showing	a	similar	prevalence	of	insulin	resistance	in	both	
genotypes.8,36	Even	though	our	study	was	not	powered	to	compare	
the	 two	groups,	we	observed	no	difference	 in	baseline	hepatic	or	
skeletal	insulin	resistance	between	patients	infected	with	Gt1	or	3	
CHC,	or	between	healthy	controls	and	CHC.
F I G U R E  5  Hepatitis	C	virus	eradication	regulates	the	mRNA	
expression	of	metabolic	genes.	Fold	change	of	13	lipogenic	(A)	
and	7	insulin	signalling	genes	(B)	with	significant	differences	
in	expression	levels	in	pre‐	and	postviral	eradication.	Data	are	
presented	as	mean	±	SE	fold	induction	compared	to	untreated	cells	
(quantified	relative	to	GAPDH),	*P < 0.05
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To	the	best	of	our	knowledge,	this	 is	the	first	study	to	demon‐
strate	 the	 significance	 of	 SAT	 adipose	 tissue	 dysfunction	 in	CHC.	
This	has	been	linked	to	other	liver	conditions,	especially	nonalcoholic	
fatty	liver	disease.22	In	our	study,	patients	with	CHC	had	adipose	tis‐
sue	insulin	resistance	as	measured	by	serum	NEFA	concentrations,	
Ra	glycerol	and	adipose	tissue	interstitial	fluid	glycerol	release.	One	
study	explored	the	effect	of	HCV	infection	on	whole	body	lipolysis.6 
Vanni	et	al	measured	serum	NEFA	levels	and	Ra	glycerol	following	
2H5‐glycerol	infusion	and	found	no	difference	in	whole	body	lipoly‐
sis	between	healthy	volunteers	and	patients	with	CHC.	Some	have	
suggested	an	association	between	HCV	infection	and	alterations	in	
adipocytokines,	but	data	have	been	inconclusive.37,38	Adipose	insu‐
lin	resistance	as	measured	by	failed	suppression	of	circulating	NEFA	
levels	 resulting	 in	 an	 increase	 in	NEFA	 delivery	 and	 availability	 in	
the	liver	and	can	fuel	lipid	accumulation.	However,	both	circulating	
NEFA	levels	and	Ra	glycerol	measurements	detect	whole	body	lip‐
olysis	and	are	unable	to	correlate	whole	body	lipolysis	to	a	specific	
tissue.	By	pairing	these	observations	with	abdominal	SAT	microdial‐
ysis	to	measure	mean	steady‐state	adipose	interstitial	fluid	glycerol	
concentrations,	we	 showed	 that	patients	with	CHC	had	 increased	
abdominal	 SAT‐specific	 insulin	 resistance	 compared	 to	 BMI‐	 and	
age‐matched	controls.
Upon	 successful	 viral	 cure,	 systemic	 insulin	 resistance	 did	 not	
alter,	but	hepatic	and	peripheral	IR	improved	in	patients	with	CHC.	
This	was	not	accompanied	by	alterations	in	body	weight	or	in	hepatic	
lipid	content.	The	improvement	in	hepatic	IR	was	more	pronounced	
in	Gt3	infected	patients	(data	not	shown),	which	was	perhaps	unsur‐
prising,	as	Gt3	HCV	 is	known	to	be	more	pro‐steatogenic	 (indeed,	
hepatic	 lipid	 content	was	higher	 in	 the	Gt3	patients	 in	our	 study),	
and	therefore,	its	eradication	would	be	expected	to	improve	hepatic	
steatosis	and	hence	hepatic	IR.	More	interestingly,	the	improvement	
in	skeletal	IR	was	only	observed	in	Gt1	CHC.	However,	we	acknowl‐
edged	that	this	study	was	not	powered	to	study	the	genotype‐spe‐
cific	contribution	to	insulin	resistance.
Sustained	virological	response	significantly	 improved	SAT	insu‐
lin	sensitivity	 in	both	Gt1&3	CHC	as	evidenced	by	 interstitial	 fluid	
glycerol	suppression	by	 insulin.	The	observed	beneficial	 impact	on	
adipose	function	could	mediate	a	reduction	 in	FFA	delivery	to	the	
liver	resulting	in	less	hepatic	steatosis.	Even	though	the	mechanisms	
that	drive	the	improvement	in	adipose	tissue	function	are	unknown,	
we	have	shown	that	they	are	occur	independent	of	the	changes	in	
body	composition	of	 fat	mass.	Taken	together,	our	data	show	that	
there	are	tissue‐specific	effects	of	viral	eradication,	namely	in	liver	
and	fat,	but	not	in	skeletal	muscle	and	our	gene	expression	data	from	
adipose	tissue	would	appear	to	endorse	this.
Our	 study	 is	 not	 without	 limitations.	 Comparison	 between	 a	
mixed	 gender	 CHC	 cohort	 and	 a	 purely	male	 control	 cohort	may	
have	 underestimated	 the	 degree	 of	 insulin	 resistance	 in	 the	CHC	
group,	as	male	subjects	are	perceived	to	have	higher	 insulin	resis‐
tance	due	 to	 the	greater	amounts	of	visceral	 and	hepatic	adipose	
tissue,	and	lack	the	protective	effect	of	oestrogen.39	The	number	of	
participants	is	small	making	it	difficult	to	extrapolate	the	relevance	
of	 observed	 metabolic	 perturbation	 in	 patients	 with	 CHC	 or	 the	
subsequent	improvements	in	tissue‐specific	insulin	sensitivity	after	
treatment.	The	small	number	of	participants	also	limits	the	interpre‐
tation	of	our	data	and	mean	that	the	analysis	of	HCV	treatment	and	
Gt	in	inducing	IR	and	hepatic	steatosis	is	likely	to	be	underpowered.	
Visceral	adipose	tissue	function	is	perhaps	the	most	critical	deter‐
minant	of	NEFA	delivery	to	the	liver,	but	real‐time	assessments	of	
visceral	 adipose	 tissue	 function	 are	not	 feasible	 in	human	 studies	
and	therefore	we	have	had	to	extrapolate	our	findings	from	the	SAT	
depot.	Not	all	CHC	patients	received	the	same	antiviral	therapies.	
Pegylated	 interferon	 has	 been	 shown	 to	 alter	 insulin	 sensitivity	
both in vivo and in vitro.40,41	Whilst	we	included	a	washout	period	
of	3‐6	months	in	our	study	design	to	eliminate	any	direct	effect(s)	of	
interferon	treatment,	we	did	observe	a	more	dramatic	improvement	
in	systemic	insulin	sensitivity	in	patients	who	did	not	receive	inter‐
feron,	but	without	any	change	in	body	composition	or	BMI.
5  | CONCLUSIONS
This	 study	 demonstrated	 that	 CHC	 is	 intricately	 linked	 to	 insulin	
resistance	 and	 hepatic	 steatosis.	 Using	 state‐of‐the‐art	 metabolic	
assessments,	we	have	demonstrated	that	both	hepatic	and	adipose	
tissue	insulin	sensitivity	improved	after	viral	eradication.	The	identi‐
fication	of	extra‐hepatic	effects	of	HCV	infection,	especially	in	the	
adipose	tissue	is	novel	and	has	important	clinical	relevance.	Further	
studies	 are	 needed	 to	 evaluate	 the	 potential	 interaction	 between	
HCV	and	adipose	tissue	in	inducing	insulin	resistance	and	the	geno‐
type‐specific	mechanisms	involved,	to	allow	for	novel	and	targeted	
therapies.
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